Transcatheter vs Surgical Valve: The Shift From Open Surgery to Catheters

The choice between a transcatheter and a surgical valve is the choice between lining a new valve inside the old one through a catheter and cutting the old valve out through the opened chest, and the shift from the second towards the first is the defining change in heart valve treatment of the past two decades. I am, in a small way, a data point in that shift. Twenty years ago my only option would have been the saw and the sternum. Instead I had a valve delivered on a wire, and I went home in two days. This is the story of how that became possible, and what it does and does not mean for you.

What the comparison actually is

The comparison is between two genuinely different things: an operation and a catheter procedure. A surgical valve is sewn in through the opened chest, on a stopped heart, with the diseased valve removed. A transcatheter valve is folded up, threaded through an artery, usually in the groin, and expanded inside the old valve, which is left where it is, while the heart keeps beating ¹.

For a patient the most visible difference is time. A transcatheter valve usually means a hospital stay of about 1 to 3 days, against roughly 5 to 7 days for surgical replacement, with recovery in weeks rather than the weeks to months that follow open surgery ². That is the difference I lived, and it is real. It is not, however, the whole story.

The evidence that changed practice

The catheter approach did not spread on enthusiasm; it spread on trials. The PARTNER and Evolut programmes tested transcatheter valves in progressively lower risk patients, starting with people considered inoperable, then high risk, then intermediate risk, and finally low surgical risk patients ³. In the low risk trials the catheter valve held its own against surgery on the outcomes that matter, which is what let guidelines widen who could be offered it ⁴.

That sequence, inoperable to high to intermediate to low, is the single most important fact in this whole field, because it is why a procedure that began as a last resort is now a mainstream option used across the risk spectrum ². When my cardiologist offered me the catheter route without a second thought, it was because two decades of that evidence sat behind the offer.

What it means for patients day to day

For the patient, the transcatheter route generally means a smaller event: often sedation rather than a general anaesthetic, a day or three in hospital, and a return to normal measured in weeks. But it carries its own pattern of risks rather than none. The one to know is the conduction system: because the valve sits where the heart’s wiring runs, about 10 to 20% of patients need a new permanent pacemaker afterwards ⁵.

There is also a small risk of a leak around the valve and of problems at the artery where the catheter went in. None of this makes the procedure a soft option; it makes it a different one, with a different risk profile from surgery. I was awake for mine, felt oddly little, and was walking the corridor the next morning, but I was also counselled carefully about the pacemaker possibility beforehand, and I was glad to have been.

It is not only the aortic valve

The shift from surgery to catheters is no longer confined to the aortic valve, which is what makes it a trend rather than a single procedure. The same principle has been carried to the mitral valve, where a transcatheter edge-to-edge repair clips the leaking leaflets together for patients at high surgical risk ². If that idea is new to you, I have explained it in MitraClip explained.

The aortic valve led simply because its shape suited a catheter delivered, expandable valve first. What followed is a broader move towards catheter based structural heart procedures, and I have set the whole arc out in advances in interventional cardiology. The direction of travel is clear, even where the destination is still being mapped.

What has not changed

For all the momentum, one thing has not been overturned: durability still favours surgery in the young. A surgical tissue valve lasts roughly 10 to 15 years, while transcatheter valves show good durability to about 5 to 8 years in trials, with longer term data still maturing ². For an older patient like me that gap may never matter; for a person with decades ahead, it can be decisive, which is why guidelines still lean towards surgery in younger, lower risk patients ⁵.

So the honest summary is not that catheters have won and surgery has lost. It is that patients now have a real choice, decided by a heart team on age, risk, and anatomy. If you want the catheter procedure explained end to end, start with what is TAVR. The shift is genuine and remarkable; it has widened the options rather than closed them.

General information, not medical advice. Whether a transcatheter or a surgical valve is right for you depends on your own heart, scans, age, and risks, and is a decision for your own heart team; please discuss the choice with a qualified cardiologist and cardiac surgeon.